PDCD1 and nasopharyngeal carcinoma: In pursuit of the novel effective treatment, several single-arm trials investigate that PD1 (CD279) inhibitors are effective in only 20–30% of recurrent or metastatic NPC patients9,10, it is urgent to develop more biomarkers to reconstruct the immune surveillance, which would be exceedingly beneficial for the clinical intervention.